Nesuparib

• CAT Number: I045099
• CAS Number: 2055357-64-5
• Molecular Formula: C23H24N6O
• Molecular Weight: 400.48
• Purity: ≥95%
• Synonyms: 6-[4-[(5-oxo-2,3,4,6-tetrahydro-1H-benzo[h][1,6]naphthyridin-8-yl)methyl]piperazin-1-yl]pyridine-3-carbonitrile
• InChI: InChI=1S/C23H24N6O/c24-13-17-4-6-21(26-14-17)29-10-8-28(9-11-29)15-16-3-5-18-20(12-16)27-23(30)19-2-1-7-25-22(18)19/h3-6,12,14,25H,1-2,7-11,15H2,(H,27,30)
• InChIKey: GRPXLKXGJAGYSD-UHFFFAOYSA-N
• SMILES: C1CC2=C(C3=C(C=C(C=C3)CN4CCN(CC4)C5=NC=C(C=C5)C#N)NC2=O)NC1

Nesuparib（Cat No.:I045099）is an investigational, orally bioavailable poly (ADP-ribose) polymerase (PARP) inhibitor designed to exploit synthetic lethality in cancer cells with DNA repair deficiencies, such as BRCA1/2 mutations. By inhibiting PARP enzymes, Nesuparib prevents DNA repair, leading to accumulation of DNA damage and selective tumor cell death. It is being evaluated for use in solid tumors, including ovarian, breast, and prostate cancers. Nesuparib aims to offer improved potency and safety over earlier PARP inhibitors. Supplied for research in targeted cancer therapy, DNA damage response, and precision oncology.